Amgen, Inc. (NASDAQ:AMGN)

generic drugs

How Amgen Can Disrupt the Market for Cholesterol Drugs

Amgen Inc. (NASDAQ: AMGN), known as a leading biotech in its field, made waves in the market on Friday morning. This biotech giant has the potential to disrupt the market ...
Read Full Story »
Biotechnology word cloud

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
fda_logo

5 Big FDA Decisions Expected in August

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, similar to that ...
Read Full Story »
thumbs up

Independent Research Firm Sees Higher Upside in Amgen

Amgen Inc. (NASDAQ: AMGN) reported strong second-quarter earnings last week. According to one independent research firm, these earnings, along with a strong pipeline and general outlook, have positioned this biotech ...
Read Full Story »
research

Amgen Earnings Point to New 52-Week High

Amgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.57 on revenues ...
Read Full Story »
biotech

What to Expect from Amgen Earnings

Amgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per ...
Read Full Story »
biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »
amgnlogo

4 Large Cap Biotech Stocks to Buy Before Earnings

The biotech industry has been on an outstanding run over the past year, and some top analysts on Wall Street think that run could be poised to continue. A new ...
Read Full Story »
Biotechnology word cloud

Short Sellers Back Off Big Biotech

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
investing

4 Defensive Stocks to Buy Now for Continued Market Volatility

While Thursday's rally was a very welcome sight, and Friday could be even better, the problems that were shaking the market are still looming right in the background. With no ...
Read Full Story »
fda_logo

5 Big Upcoming FDA Decisions Expected in July

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, similar to that ...
Read Full Story »
DNA

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Sellers Lose Some Conviction Against Big Biotech

The short interest data are out for the May 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »